Skip to main content
HairCited

Espironolactona para Perda Capilar de Padrão Feminino

A

Baseado em 19 estudos (2 meta-analyses, 4 RCTs) com 5,743 participantes no total. 16/19 estudos mostram efeitos positivos.

<\/script>\n
`; }, get iframeSnippet() { const domain = 'haircited.com'; const params = 'ingredient\u003Dspironolactone\u0026condition\u003Dfemale\u002Dpattern\u002Dhair\u002Dloss'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

A

Conclusão

Spironolactone is strongly supported by research as an effective option that may help women with female pattern hair loss, with both oral and topical formulations showing benefits in clinical trials.

  • 84% of studies show positive effects, including 4 RCTs focused on women
  • Both oral and topical formulations have demonstrated benefits
  • A dedicated meta-analysis confirms efficacy and safety in female pattern hair loss
  • Combination with minoxidil may offer enhanced results

Key Study Findings

Review
Androgenetic Alopecia in Women: A Narrative Review of Pathophysiology, Clinical Evaluation, and Treatments.
Dose: None vs: None Outcome: None Efeito: None None

População: women with androgenetic alopecia (female pattern hair loss)

Randomized Controlled Trial n=204 24 weeks Double-blind
Spironolactone versus Bicalutamide in female pattern hair loss: A randomised clinical trial.
Dose: Bicalutamide 50 mg/day; spironolactone 100 mg/day vs: Spironolactone 100 mg/day Outcome: Hair density and shaft diameter change at 24 … Efeito: Frontal: +5.05 vs +3.13 hairs/cm2 (diff 1.92) P < 0.001 (frontal); P = 0.028

População: Women 18-50 with Sinclair Grade II-V FPHL (India)

randomized controlled trial n=80 24 weeks Single-blind
Evaluation of the Efficacy and Safety of Topical Spironolactone versus Topical Minoxidil in the Treatment …
Dose: Group A: 1% topical spironolactone gel twice daily; Group B: 5% topical minoxidil gel twice daily vs: Placebo Efeito: Both groups showed statistically significant improvement. Group A: 10 mild, 16 moderate, 2 excellent None
RCT n=48 24 weeks Double-blind
Efficacy and safety of oral spironolactone for female pattern hair loss in premenopausal women: a …
Dose: Spironolactone 100 mg once daily vs: Placebo Efeito: Terminal hair counts: 9.48 vs 5.32 hairs/cm2; hair diameter: 4.23 vs 2.96 μm; moderate-to-marked imp p=0.063 (terminal hair counts)
Randomized Controlled Trial n=240 520 weeks Open-label
Nutritional deficiencies after sleeve gastrectomy and Roux-en-Y gastric bypass at 10 years: secondary analysis of …
Dose: None vs: Laparoscopic Roux-en-Y gastric bypass (LRYGB) Outcome: Nutritional deficiency prevalence at 10 years Efeito: Iron deficiency: LSG 14% vs LRYGB 41% p=0.017 (iron deficiency)

População: Severely obese adults undergoing bariatric surgery

Review
Male and female pattern hair loss.
Dose: None vs: Placebo Efeito: None None

Key Statistics

45

Estudos

6441

Participantes

Positive

A

Nota

Referenced Papers

Australian prescriber 2025 2 citações
Journal of cosmetic … 2023 3 citações
Journal of the … 2020 43 citações
Clinical and experimental … 2020 20 citações
International journal of … 2018 129 citações
Australian journal of … 2018 8 citações
The Cochrane database … 2016 18 citações
The Medical clinics … 2015 66 citações
Journal of the … 2015 50 citações
Clinical obstetrics and … 2015 9 citações
Current problems in … 2015 8 citações
Der Hautarzt; Zeitschrift … 2013 19 citações
International journal of … 2013
The Australasian journal … 2011 44 citações
Skinmed 2010 33 citações
Seminars in cutaneous … 2009 4 citações
Duodecim; laaketieteellinen aikakauskirja 2006
Journal of the … 2005 247 citações
The British journal … 2005 205 citações
Journal of the … 2005 64 citações

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

Dosagens Comumente Utilizadas

hairloss:
100-200 mg/day (prescription)

Limite superior: 200 mg/day (hair loss indication)

Dosagens Estudadas em Pesquisas

Dosagem Duração Efeito N
None -- Neutral --
Bicalutamide 50 mg/day; spironolactone 100 mg/day 24 weeks Positive 204
Group A: 1% topical spironolactone gel twice daily; Group B: 5% topical minoxidil gel twice daily 24 weeks Positive 80
Spironolactone 100 mg once daily 24 weeks Positive 48
None 520 weeks Positive 240
None -- Positive --
Group A: topical finasteride 1% solution; Group B: topical spironolactone 5% solution; Group C: topi 16 weeks Positive 45
4 g -- Neutral --

Melhor horário: Once or twice daily with food; prescription required

Safety & Side Effects

Efeitos Colaterais Relatados

  • Menstrual irregularities
  • Breast tenderness
  • Hyperkalemia (elevated potassium levels)
  • Dizziness and orthostatic hypotension
  • Frequent urination

Interações Conhecidas

  • ACE inhibitors and ARBs (increased hyperkalemia risk)
  • Potassium supplements and potassium-sparing diuretics (dangerous hyperkalemia)
  • NSAIDs (may reduce diuretic effectiveness and increase kidney risk)
  • Digoxin (spironolactone may increase digoxin levels)

Ingestão máxima tolerável: 200 mg/day (hair loss indication)

Consulte sempre o seu profissional de saúde antes de iniciar qualquer suplemento.Sempre consulte seu profissional de saúde antes de iniciar qualquer suplemento.

Frequently Asked Questions

Does Espironolactona help with Perda Capilar de Padrão Feminino?
Based on 45 studies with 6,441 participants, there is strong evidence from multiple clinical trials that Espironolactona may support Perda Capilar de Padrão Feminino management. Our evidence grade is A (Strong Evidence).
How much Espironolactona should I take for Perda Capilar de Padrão Feminino?
Studies have used various dosages. A commonly studied range is 100-200 mg/day (prescription). Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Espironolactona?
Reported side effects may include Menstrual irregularities, Breast tenderness, Hyperkalemia (elevated potassium levels), Dizziness and orthostatic hypotension. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Espironolactona and Perda Capilar de Padrão Feminino?
We rate the evidence as Grade A (Strong Evidence). This rating is based on 45 peer-reviewed studies with 6,441 total participants. The overall direction of effect is positive.

Related Evidence

Espironolactona para outras condições

Aviso Legal da FDA: Estas declarações não foram avaliadas pela Food and Drug Administration. Os produtos e informações neste site não se destinam a diagnosticar, tratar, curar ou prevenir qualquer doença. As notas de evidência apresentadas são baseadas em nossa análise de pesquisas revisadas por pares publicadas e não constituem aconselhamento médico. Sempre consulte seu profissional de saúde antes de iniciar qualquer regime de suplementação.